Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Leslie Smetzer"'
Autor:
Amita Patnaik, Gina L. Mangold, Aracely Cavazos, Cathy Alvarez, Michael J. Wick, Brianne Kaiser, Theresa A. Mays, Leslie Smetzer, Shelly Gunn, Lon S. Smith, Drew W. Rasco, Muralidhar Beeram, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Toshio Shimizu
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways.Experimental Design: We investigated safety, efficacy, and correlations between tumor genetic alterations and clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e2b10c252893d51952e3f8ce17d8331
https://doi.org/10.1158/1078-0432.c.6520148
https://doi.org/10.1158/1078-0432.c.6520148
Autor:
Amita Patnaik, Gina L. Mangold, Aracely Cavazos, Cathy Alvarez, Michael J. Wick, Brianne Kaiser, Theresa A. Mays, Leslie Smetzer, Shelly Gunn, Lon S. Smith, Drew W. Rasco, Muralidhar Beeram, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Toshio Shimizu
CCR Translation for This Article from The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0405355b2f161ed76f219909d069b7
https://doi.org/10.1158/1078-0432.22444388
https://doi.org/10.1158/1078-0432.22444388
Autor:
Shazli N. Malik, Lisa A. Hammond, Leslie Smetzer, Elzbieta Izbicka, Anthony W. Tolcher, Amita Patnaik, Jeffrey I. Kreisberg, Eric K. Rowinsky, David Bushnell, Howard Fingert, Garry Schwartz, Ian M. Thompson, John G. Kuhn
Publikováno v:
Clinical Cancer Research. 10:5048-5057
Purpose: To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to the Bcl-2 mRNA, with docetaxel to patients with hormone-refractory prostate cancer; to characterize the pertinent pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0dce4835a12df7f0dc138d9ff8fd4c
https://doi.org/10.1158/1078-0432.ccr-03-0701
https://doi.org/10.1158/1078-0432.ccr-03-0701
Autor:
P. Ravdin, Eric K. Rowinsky, N. Peacock, H. A. Burris, Leslie Smetzer, Lon Smith, R. Bellet, G.I Rodriguez, C. Aylesworth, T. Petit, D. D. Von Hoff
Publikováno v:
Annals of Oncology. 10:223-230
Purpose: This study was undertaken to evaluate the feasibility of administering docetaxel (Taxotere; Rhone-Poufenc-Rorer) as a one-hour intravenous (i.v.) infusion on day I combined with 5-fluorouracil (5-FU) as a bolus i.v. injection for five (days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53440b657514b9f66a601c166052e078
https://doi.org/10.1023/a:1008356025108
https://doi.org/10.1023/a:1008356025108
Autor:
H. A. Burris, R. Atsumi, T. Oguma, Leslie Smetzer, J. G. Kuhn, K. Masuo, L. Higashi, D. D. Von Hoff, R. Barrington, Mace L. Rothenberg, K. Sudo, John R. Eckardt, Suzanne M. Fields, G. I. Rodriguez, David Rinaldi, Geoffrey R. Weiss, S. G. Eckhardt
Publikováno v:
Annals of Oncology. 7:491-496
Summary Background Tecogalan sodium is an angiogenesis inhibitor isolated from a sulfated polysaccharide produced by the bacterium Arthrobacter. The antiangiogenic effect of tecogalan sodium is thought to be mediated by the inhibition of binding of b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b86f2a44f8afa29e842436a597cf02
https://doi.org/10.1093/oxfordjournals.annonc.a010638
https://doi.org/10.1093/oxfordjournals.annonc.a010638
Autor:
Kyriakos P. Papadopoulos, Drew W. Rasco, Aracely Cavazos, Muralidhar Beeram, Cathy Alvarez, Lon Smith, Michael J. Wick, Shelly Gunn, Theresa Mays, Amita Patnaik, G. Mangold, Brianne Kaiser, Anthony W. Tolcher, Leslie Smetzer, Toshio Shimizu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(8)
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We investigated safety, efficacy, and correlations between tumor genetic alterations and clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8856e3bb5b591d61d8a8130f82c7770
https://pubmed.ncbi.nlm.nih.gov/22392916
https://pubmed.ncbi.nlm.nih.gov/22392916
Autor:
Leslie, Smetzer
Publikováno v:
ONS connect. 22(10)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ff7a9c30ab9e05bf32a19ca268f5a02e
https://pubmed.ncbi.nlm.nih.gov/18074627
https://pubmed.ncbi.nlm.nih.gov/18074627
Autor:
Anthony W. Tolcher, Jill Van Wart Hood, Amita Patnaik, Chris H. Takimoto, Johann S. de Bono, Desirée Hao, Alexander R. Miller, Eric K. Rowinsky, Leslie Smetzer, Lisa A. Hammond, S. Gail Eckhardt, Dan Von Hoff, James A. Merritt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(13)
Purpose The purpose of this study was to assess the feasibility of administering Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene to patients with advanced malignancies, characterize the pertinent pharmacokinetic parameters, identif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613eb5d26e3de6285b65322ec3d048d0
https://pubmed.ncbi.nlm.nih.gov/16648505
https://pubmed.ncbi.nlm.nih.gov/16648505
Autor:
Bahram, Forouzesh, Chris H, Takimoto, Andrew, Goetz, Sami, Diab, Lisa A, Hammond, Leslie, Smetzer, Garry, Schwartz, Robert, Gazak, John T, Callaghan, Daniel D, Von Hoff, Eric K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(15)
This study was conducted to assess the feasibility of administering the oral diarylsulfonylurea (DSU) ILX-295501 on a weekly for 3 weeks every 4-week schedule. The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::78caf57e00079431e4ef2329b32c0746
https://pubmed.ncbi.nlm.nih.gov/14654534
https://pubmed.ncbi.nlm.nih.gov/14654534
Autor:
Mitchell A, Garrison, Lisa A, Hammond, Charles E, Geyer, Garry, Schwartz, Anthony W, Tolcher, Leslie, Smetzer, Jose A, Figueroa, Murray, Ducharme, John, Coyle, Chris H, Takimoto, Robert L, De Jager, Eric K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(7)
The purpose of this study was to assess the feasibility of administering exatecan, a water-soluble, potent camptothecin analogue, as a protracted 21-day continuous i.v. infusion (CIVI). The study also sought to determine the maximum tolerated dose (M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2deaf4ebf044945fb7b94b8c12f3a06
https://pubmed.ncbi.nlm.nih.gov/12855627
https://pubmed.ncbi.nlm.nih.gov/12855627